Wird geladen...
Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program
BACKGROUND: Disease modifying treatments (DMT) for MS such as interferon beta (IFNβ) have been shown to reduce the risk for disease progression. Therefore adherence to treatment is essential for treatment outcome.Here we want to evaluate if participation in a patient management program (PMP) improve...
Gespeichert in:
Veröffentlicht in: | BMC Neurol |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artigo |
Sprache: | Inglês |
Veröffentlicht: |
BioMed Central
2015
|
Schlagworte: | |
Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4580346/ https://ncbi.nlm.nih.gov/pubmed/26395989 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-015-0426-x |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|